Skip to main content
PeptideHackerLab
By Peptide Hacker Lab Research Team Published

TE-8214 Extended Octreotide Exposure to 5.5 Days: What the 2026 Phase 1 Study Shows

A peer-reviewed paper published in Frontiers in Endocrinology on August 25, 2026 reports the first human pharmacokinetic results for TE-8214, an investigational octreotide analog engineered with two fatty-acid groups and a hydrophilic linker.[1] The paper combines peptide design, albumin- and receptor-binding assays, animal pharmacology, toxicology, and a 32-person Phase 1 trial.[1]

The headline result is a mean terminal half-life of 131.0 hours, or about 5.5 days, after the highest tested single dose in healthy adults.[1] The same cohort had an exploratory mean IGF-1 change of minus 22.5% from baseline on day 28.[1]

Those findings show prolonged exposure and pharmacodynamic activity.[1]

They do not show that TE-8214 treats acromegaly, controls neuroendocrine-tumor symptoms, shrinks tumors, or improves a patient outcome.[1] The clinical portion used healthy volunteers, tested one dose per participant, and was not designed as an efficacy trial.[1][2]

The primary paper is available under DOI 10.3389/fendo.2026.1871977, and the trial is registered as NCT06372652.[1][2]

What changed on August 25, 2026

The new event is publication of the full first-in-human dataset, not initiation or completion of the trial.[1][2]

ClinicalTrials.gov records a June 18, 2024 study start, an October 10, 2024 primary completion date, and a December 6, 2024 study completion date.[2] The journal records receipt on May 4, 2026, acceptance on August 5, and publication on August 25.[1]

The paper adds four material findings:[1]

  1. A dual-fatty-acid module can be attached to an octreotide-derived pharmacophore while retaining SSTR2-linked activity in the reported assays.[1]
  2. TE-8214 was more than 99.99% protein-bound under the study’s cross-species equilibrium-dialysis conditions, with unbound concentrations below the assay’s quantification limit.[1]
  3. Single-dose human exposure increased across the tested cohorts, and the reported terminal half-life reached 5.5 days at the highest dose.[1]
  4. IGF-1 remained at least 12% below baseline from day 4 through day 28 in that cohort, with a day-28 mean change of minus 22.5%.[1]

The durable contribution is a translation of an albumin-binding design from chemistry into measured human pharmacokinetics.[1] The clinical result is still an early biomarker and exposure study rather than evidence of therapeutic benefit.[1]

How TE-8214 was engineered

Octreotide is a cyclic somatostatin analog that acts through somatostatin receptors, particularly SSTR2 in the disease contexts discussed by the authors.[1] TE-8214 keeps an octreotide-derived receptor-binding segment but changes the larger molecular architecture.[1]

The construct includes three functional parts:[1]

  • an octreotide-derived pharmacophore with a tyrosine substitution
  • a branched, hydrophilic (PEG4Lys)2 linker
  • two different fatty-acid groups, described as C16-CH3 and C18-COO-minus

The linker is intended to separate the receptor-binding portion from the lipidated albumin-binding module while preserving aqueous solubility.[1] The two fatty acids are intended to engage albumin’s fatty-acid-binding pockets and create a reversible circulating reservoir.[1]

That mechanism differs conceptually from an injection-site depot.[1] A depot prolongs apparent exposure by releasing drug slowly from the administration site. The TE-8214 model instead proposes relatively rapid absorption followed by slow systemic clearance because most peptide is reversibly associated with circulating albumin.[1]

The site’s peptide pharmacokinetics and bioavailability guide explains why absorption, distribution, protein binding, free concentration, and terminal half-life are separate measurements. The CJC-1295 with DAC overview provides an adjacent example of albumin binding as a half-life-extension strategy, without implying that the two molecules have the same chemistry or pharmacology.

What the binding and cell experiments show

Surface plasmon resonance produced an apparent human-serum-albumin dissociation constant of 1.86 micromolar by kinetic analysis and 6.83 micromolar by steady-state analysis.[1] The authors noted that the disagreement may reflect a more complex interaction than the fitted one-to-one model because albumin contains multiple fatty-acid-binding sites.[1]

In equilibrium-dialysis experiments using mouse, rat, dog, monkey, and human plasma, the measured free TE-8214 concentration remained below the assay’s 1 nanogram-per-milliliter lower limit of quantification.[1] The authors therefore reported greater than 99.99% protein binding across the tested concentrations and species.[1]

That is strong evidence that the construct was predominantly protein-bound under those assay conditions.[1] It is not a precise measurement of the very small unbound fraction because the assay could not quantify it.[1] This limitation matters: total plasma concentration can be measured while the receptor-accessible free concentration remains uncertain.[1]

TE-8214 also bound SSTR2 in the reported surface-plasmon-resonance assay and reduced cAMP in SSTR2-expressing cell models with potency similar to octreotide.[1] Cell assays also showed reductions in serotonin, chromogranin A, and viability readouts under selected conditions.[1]

These experiments support retained receptor-linked function after lipidation.[1] They do not establish receptor selectivity across all five somatostatin-receptor subtypes, clinical antitumor activity, or equivalence to octreotide in patients.[1]

The animal package: useful translation, small pharmacology groups

TE-8214 had reported terminal half-lives of approximately 27 to 28 hours in rats and 6.3 days in three beagle dogs.[1] In animal pharmacodynamic experiments, exposure was accompanied by prolonged reductions in serotonin, growth hormone, or IGF-1, depending on the model.[1]

The animal studies provided a bridge from albumin binding to prolonged exposure and then to endocrine biomarkers.[1] They also had important limits.[1] The exploratory pharmacology groups commonly included only three or four animals, and those experiments were not randomized or blinded.[1]

The larger toxicology program used repeated administration in 160 rats and 40 dogs.[1] The paper reports a rat no-observed-adverse-effect level at the highest tested dose and a lower dog threshold because splenic congestion at the highest dog dose was considered potentially adverse.[1]

These toxicology studies informed first-in-human dose selection.[1] They cannot substitute for a larger human safety dataset, especially for uncommon events, chronic exposure, or disease-specific risks.[1]

Phase 1 design: randomized and blinded, but only 32 healthy adults

The registered study was a randomized, double-blind, placebo-controlled, single-ascending-dose Phase 1 trial sponsored by Immunwork.[1][2] Thirty-two healthy adults were enrolled at one Australian site: six participants received TE-8214 in each of four dose cohorts, and eight received placebo across the cohorts.[1]

The tested single doses were 0.6, 1.2, 2.0, and 4.0 milligrams, administered subcutaneously with a 30-gauge needle.[1] These are study-design facts, not dosing guidance. Dose escalation required review of blinded safety data and available pharmacokinetic and pharmacodynamic information.[1]

The evidence hierarchy was explicit:[1][2]

Evidence layerPrespecified roleWhat it can establish
Safety and tolerabilityPrimaryCommon short-term observations after one dose in this small sample
PharmacokineticsSecondaryConcentration-time behavior and estimated PK parameters
IGF-1ExploratoryPharmacodynamic activity consistent with somatostatin-receptor engagement
Patient efficacyNot testedNo conclusion about symptom, biochemical-control, or tumor outcomes

All 32 participants completed the study.[1] Follow-up lasted 56 or 84 days depending on cohort and enrollment timing.[1] The single-dose design avoided prolonged repeated suppression in healthy volunteers, but it also means the study cannot characterize steady-state accumulation or repeated-dose tolerability.[1]

Human pharmacokinetics: prolonged total exposure

Systemic exposure increased with dose, and mean terminal half-life estimates ranged from 91 to 131 hours across the cohorts.[1] At 4.0 milligrams, the mean estimate was 131.0 plus or minus 32.6 hours, equivalent to 5.5 plus or minus 1.4 days.[1]

This is a total-plasma-concentration result.[1] Because the unbound concentration was below quantification in the protein-binding experiments, the paper could not connect pharmacodynamic response to measured free-drug exposure.[1] The authors also caution that total TE-8214 concentrations cannot be compared directly with total octreotide concentrations because their protein-bound fractions differ.[1]

A prior independent Phase 1 study randomized 122 healthy participants while evaluating several subcutaneous octreotide depots and octreotide LAR.[3] That study found sustained release for up to four weeks and IGF-1 suppression, illustrating that a depot can also produce prolonged octreotide exposure.[3]

The comparison is useful but indirect.[1][3]

TE-8214 and the earlier depot formulations were not tested head to head in one randomized trial, and differences in assay, protein binding, formulation, dose, sampling, and participants prevent a simple superiority claim.[1][3]

The LC-MS peptide quantification guide explains why assay specificity, lower limits of quantification, total-versus-free analyte, and degradation products determine what a concentration result actually means.

IGF-1 changed, but this was not an efficacy endpoint

At day 28, the 4.0-milligram cohort had a mean IGF-1 change of minus 22.5% from baseline, with a reported p value of 0.0367.[1] IGF-1 remained at least 12% below baseline from day 4 through day 28 in that cohort.[1] Placebo changes over the reported interval ranged from plus 5.7% to minus 7.7%.[1]

This temporal alignment supports pharmacodynamic activity over the period when TE-8214 remained measurable.[1] It does not establish biochemical control in acromegaly because the participants did not have acromegaly and began with normal physiology.[1]

Growth hormone could not provide a meaningful parallel endpoint in this study.[1] The paper reports concentrations at 0.1 micrograms per liter regardless of treatment, making a treatment effect uninterpretable against the low, pulsatile baseline of healthy adults.[1]

The site’s growth hormone axis guide separates pulsatile GH secretion from the more integrated IGF-1 readout. The IGF-1 signaling overview adds pathway context, but neither biomarker should be treated as a substitute for a clinical outcome.

Safety findings and the boundaries of a small single-dose trial

No deaths, serious adverse events, or grade 3 or higher treatment-emergent adverse events were reported.[1] Overall treatment-emergent adverse-event incidence was 70.8% among TE-8214 recipients and 87.5% among placebo recipients.[1]

The paper reports no injection-site pain, itching, induration, or nodules.[1] Transient bruising and redness lasted one or two days in some participants.[1]

Those findings support short-term tolerability under the tested conditions.[1] They do not establish chronic safety or rule out uncommon harms.[1] Only 24 people received TE-8214, each active cohort contained six participants, and no participant received repeated doses.[1]

The funding and conflict disclosures also matter when weighing the result.[1] Immunwork sponsored the clinical study and funded all study costs; most authors were employees, founders, advisers, or equity holders connected with Immunwork, T-E Meds, or their parent company.[1] Industry involvement does not invalidate the measurements, but it increases the value of independent replication, transparent data access, and confirmatory patient studies.

Receptor desensitization remains unanswered

TE-8214 produced prolonged pharmacodynamic activity after one administration.[1] The study did not directly measure SSTR2 phosphorylation, beta-arrestin recruitment, internalization, recycling, downregulation, or response after repeated human exposure.[1]

That gap matters because a long half-life changes the temporal pattern of receptor exposure. Persistent total plasma concentration does not guarantee persistent free concentration, and persistent free concentration does not guarantee unchanged receptor responsiveness.

The receptor desensitization and cycling guide provides the appropriate framework: separate ligand exposure from receptor availability, downstream signaling, and recovery. A future repeated-dose study should pair pharmacokinetics with receptor-proximal biomarkers and test whether the exposure-response relationship changes over time.

What the study does and does not establish

Supported by the reported evidence

  • TE-8214 is a dual-fatty-acid-conjugated octreotide analog formulated as an aqueous solution.[1]
  • The construct bound albumin and SSTR2 and retained octreotide-like activity in selected cell assays.[1]
  • TE-8214 was predominantly protein-bound under the reported equilibrium-dialysis conditions.[1]
  • Single-dose human exposure increased across the tested cohorts.[1]
  • The highest cohort had a mean terminal half-life of about 5.5 days.[1]
  • Exploratory IGF-1 suppression persisted through day 28 in that cohort.[1]
  • No serious or grade 3 or higher treatment-emergent adverse event was reported in the 32-person trial.[1]

Not established

  • efficacy in acromegaly or neuroendocrine-tumor patients[1]
  • symptom relief, tumor response, progression control, or quality-of-life benefit[1]
  • repeated-dose or steady-state human pharmacokinetics[1]
  • long-term or uncommon human safety outcomes[1]
  • the precise unbound TE-8214 concentration in plasma[1]
  • superiority to octreotide LAR, another depot, lanreotide, or oral octreotide[1][3]
  • absence of receptor desensitization during chronic exposure[1]
  • regulatory approval or a clinical dosing schedule[1][2]

What researchers should watch next

Repeated-dose pharmacokinetics

A patient study should measure accumulation, trough-to-peak variability, time to steady state, apparent clearance, and washout after repeated administration. Total and unbound concentrations should be distinguished if analytical sensitivity permits.

Clinical populations

The next evidence should come from people with acromegaly or functioning neuroendocrine tumors rather than healthy volunteers.[1] Endpoints should include disease-appropriate hormone control, symptoms, imaging where relevant, rescue treatment, discontinuation, and patient-reported administration burden.

Direct comparator data

A controlled comparison with an approved or established somatostatin-analog strategy would test whether the aqueous albumin-binding approach changes variability, injection-site experience, biochemical control, or adherence. Historical comparisons cannot answer that question reliably.[1][3]

Receptor-response durability

Repeated exposure should be paired with pharmacodynamic sampling dense enough to identify tachyphylaxis, altered exposure-response slopes, or recovery between administrations. Mechanistic substudies could evaluate SSTR2 trafficking and downstream signaling.

Analytical confirmation

More sensitive assays should attempt to quantify unbound intact TE-8214 and relevant degradation products. The site’s in vitro peptide stability testing guide explains why plasma stability, formulation stability, and in vivo exposure are related but distinct questions.

Independent confirmation

The company-funded, company-authored development package should be reproduced or audited through independent clinical sites, prespecified analyses, complete adverse-event reporting, and accessible results.[1]

Bottom line

The August 25, 2026 paper is a credible first-in-human pharmacokinetic development.[1][2] Its strongest result is that a dual-fatty-acid, albumin-binding octreotide analog produced a measured mean terminal half-life of about 5.5 days and an exploratory IGF-1 signal lasting through day 28 after one injection in healthy adults.[1]

Its central limitation is equally clear.[1] This was a 32-person, single-dose Phase 1 study, only 24 participants received TE-8214, free-drug exposure was not quantifiable, and no patient efficacy endpoint was tested.[1]

Researchers now have a human proof of pharmacokinetic concept for the dual-fatty-acid platform.[1] They do not yet have evidence that TE-8214 improves clinical outcomes, remains effective and safe with repeated exposure, avoids receptor adaptation, or outperforms established somatostatin-analog formulations.[1][3]

This guide is for scientific education only. It does not provide medical advice, treatment, dosing, or sourcing guidance.

Sources

[1] https://doi.org/10.3389/fendo.2026.1871977 — A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids

“At the highest human dose (4.0 mg), TE-8214’s half-life (131.0 ± 32.6 hours, i.e., 5.5 ± 1.4 days) overlapped with the canine estimate (6.3 ± 0.5 days) within experimental error (Figure 4B).” “This work received no external grant funding; all study costs were funded by Immunwork, Inc., Taiwan.” “This study has several limitations.” “No deaths, serious adverse events (SAEs), or Grade ≥3 TEAEs occurred in any cohort (Supplementary Table 8).” “At Day 28, TE-8214 at 4.0 mg reduced IGF-1 by 22.5% levels relative to baseline (mean change −22.5%; p = 0.0367, Figure 8B), whereas the placebo group yielded no significant IGF-1 changes (+5.7% to −7.7%).” “Overall TEAE incidence was comparable between participants receiving TE-8214 (70.8%) and placebo (87.5%).” [2] https://clinicaltrials.gov/study/NCT06372652 — A Phase 1 Study of TE-8214 Solution in Healthy Volunteers “A Randomized, Double-blinded, Placebo-controlled Phase 1 Study of a Single Dose of a Subcutaneous Ultra-Long-Acting Somatostatin Analog (TE-8214 Solution) to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers” “Safety and tolerability of TE-8214 by the incidence of treatment-emergent adverse events (TEAEs)” [3] https://doi.org/10.1111/bcp.12698 — Octreotide subcutaneous depot in healthy volunteers “One hundred and twenty-two subjects were randomized.” “For all depot variants, onset of octreotide release was rapid and sustained for up to 4 weeks.”